Given the therapeutic efficacy of [177Lu]-J591, this finding shows that J591 targets an epitope on the extracellular domain of PSMA solely available on PSMA exposed to prostate cancer cells and not on healthy cells. Here, FOLH1 is linked to prostate cancer.